Veru Inc
Change company Symbol lookup
Select an option...
VERU Veru Inc
CPNG Coupang Inc
BELFB Bel Fuse Inc
CTKYY CooTek (Cayman) Inc
WAB Westinghouse Air Brake Technologies Corp
HMBL Humbl Inc
LGDTF Liberty Gold Corp
RGS Regis Corp
AMX America Movil SAB de CV
HSY Hershey Co
Go

Consumer Staples : Personal Products | Small Cap Growth
Company profile

Veru Inc. is an oncology biopharmaceutical company. The Company is focused on developing medicines for the management of breast and prostate cancers. The Company's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. It has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Closing Price
$5.61
Day's Change
0.10 (1.81%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.84
Day's Low
5.36
Volume
(Light)
Volume:
1,791,179

10-day average volume:
7,270,251
1,791,179

Display:

Providers:

UpdateCancel
4 providers
November 10, 2022
Manufacturing hub Guangzhou is latest Chinese city to face lockdowns as COVID cases rise

By Ciara Linnane U.S. cases are rising by double digits in 22 states The southern Chinese manufacturing hub of Guangzhou is the latest to see lockdowns amid a surge in COVID-19 cases, as the government presses ahead with the strict...(MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.